ICON plc — FY 2016 Form 20-F
Reporting period: Year ended December 31, 2016; filed February 28, 2017. This is an annual report, not a standalone Q4 filing, and the supplied filing text does not provide a clear value for Q4-only results. Financial statements are in U.S. dollars and prepared under U.S. GAAP.
Business context
ICON is an Ireland-based global contract research organization providing clinical development and related services to pharmaceutical, biotechnology and medical-device companies. At year-end it had approximately 12,500 employees across 87 locations in 38 countries. It reported one operating segment.
Financial results and liquidity
| Metric | FY 2016 | FY 2015 | Change |
|---|---|---|---|
| Gross revenue | $2,365.0 million | $2,161.6 million | 9.4% |
| Reimbursable expenses | $698.5 million | $586.6 million | — |
| Net revenue | $1,666.5 million | $1,575.0 million | 5.8% |
| Income from operations | $311.7 million | $281.5 million | 10.7% |
| Operating margin on net revenue | 18.7% | 17.9% | Up 0.8 percentage points |
| Net income | $262.2 million | $239.5 million | 9.5% |
| Diluted earnings per share | $4.65 | $3.97 | 17.1% |
| Cash from operating activities | $259.2 million | $279.1 million | Down 7.1% |
Net revenue grew 6.4% in constant currency and 3.2% on a constant-dollar organic basis. Operating income excluding the $8.2 million restructuring charge was $319.9 million, or 19.2% of net revenue. The effective tax rate was 12.7%, versus 14.1% in 2015. Direct costs were 57.7% of net revenue in both years; SG&A declined to 19.5% of net revenue from 20.7%.
Cash and short-term investments totaled $260.6 million at year-end ($192.5 million cash and $68.0 million investments), versus $189.9 million in 2015. Working capital was $463.6 million. Capital expenditure was $42.6 million. Revenue outstanding increased to 50 days from 41 days, contributing to lower operating cash flow. The $350 million Senior Notes had a 3.64% stated fixed rate, maturing in December 2020; the company reported no revolver borrowings at year-end. The balance-sheet carrying amount of the notes was $348.5 million.
Material changes and significant events
- U.S. net revenue rose 17.3% to $763.8 million, while Rest of Europe declined 5.2% to $313.2 million and Ireland declined to $410.6 million. Regional revenue allocation is affected by the company’s transfer-pricing model.
- ICON acquired Clinical Research Management, Inc. (ClinicalRM) in September 2016, with initial net cash outflows of $52.4 million and up to $12 million of additional milestone consideration. ClinicalRM expands U.S. government-sponsored research capabilities.
- Backlog increased to approximately $4.2 billion from $3.9 billion. Management cautions that backlog may be delayed or cancelled and is not a reliable assurance of future revenue.
- The company began a share repurchase program of up to $400 million in October 2016; it redeemed 1,429,187 shares for $110 million by year-end. Outstanding shares were 54,530,843 at December 31, 2016.
- One customer contributed 26% of net revenue, down from 31% in 2015; the top five customers contributed 45%, versus 49%.
Outlook, risks and unusual items
The filing provides no quantified revenue or earnings guidance. Management describes continued opportunities from outsourcing, strategic CRO partnerships, demand for global trials, technology-enabled services and real-world data, while emphasizing execution, quality, patient recruitment and operational efficiency. Management expected approximately $45.2 million of investment in IT, existing facilities and new offices over the next 12 months, and stated it believed foreseeable cash needs could be funded through operating cash flow, cash balances and available facilities.
- Key business risks include customer concentration; project cancellation, delays and fixed-fee cost overruns; dependence on pharmaceutical and biotech R&D spending and outsourcing; competition and vendor consolidation; and the ability to recruit and retain qualified staff, investigators and patients.
- Clinical-trial execution, regulatory compliance, patient safety, privacy and cybersecurity failures could cause data loss, repeat work, litigation, penalties or reputational harm. Insurance and customer indemnities may not cover all losses.
- Foreign-exchange exposure affects translation and costs versus contract currencies. The company also identifies tax uncertainty, including audits and $26.6 million of unrecognized tax benefits at year-end.
- Debt covenants restrict certain actions and include leverage and interest-coverage requirements. The company had $350 million principal outstanding; a $100 million revolving facility was undrawn at year-end.
- The $8.2 million restructuring charge comprised $6.2 million of workforce rationalization and $2.0 million for an onerous lease obligation. The ClinicalRM acquisition included provisional purchase accounting and contingent consideration.
- Operating lease commitments totaled $152.5 million. Management reported no litigation expected to have a material adverse effect. No cash dividends were paid, and none were planned for the foreseeable future.
KPMG issued unqualified opinions on the consolidated financial statements and the effectiveness of internal control over financial reporting; management also concluded disclosure controls were effective.
Important facts for investors to verify
- How much of net revenue growth and backlog conversion is organic, and whether higher revenue outstanding (50 days versus 41) reverses.
- Whether operating margin improvement is sustainable after excluding the restructuring charge, and how regional profitability develops, particularly in the U.S.
- ClinicalRM’s integration, performance against milestones and any further consideration due.
- Customer concentration, including the largest client’s 26% share, and the renewal or performance terms of strategic partnerships.
- Cash generation and capital allocation, including the remaining capacity and pace of the $400 million buyback, planned investment and debt covenant headroom.
- The eventual effect of the forthcoming revenue-recognition standard on contract measurement, reported revenue and backlog disclosures; the filing says the impact was still under evaluation.